Cell/Gene Tx channel feed

Swedish biotech rais­es €30M Se­ries A to de­vel­op off-the-shelf gene ther­a­py for sol­id tu­mors

Last year
Financing
Startups

Re­genxbio gives glimpse at ear­ly Duchenne gene ther­a­py re­sults, plans piv­otal study for ac­cel­er­at­ed ap­proval

Last year
R&D

Ex­clu­sive: Backed by MIT’s An­drew Lo, Quan­tile Health rais­es $6M to bol­ster gene ther­a­py ac­cess

Last year
Financing

'Sweet spot' of CNS cell ther­a­py: Ke­nai emerges with $82M for Parkin­son's study

Last year
Financing
Startups

Sarep­ta touts Duchenne gene ther­a­py up­take, but warns of de­mand flat­ten­ing be­fore po­ten­tial ex­pand­ed la­bel from FDA

Last year
Pharma

Io­vance’s Am­tagvi sees ‘healthy de­mand’ af­ter US ap­proval

Last year
Pharma
Manufacturing

Ac­cel­er­at­ed ap­proval will be 'the nor­m' for gene ther­a­pies, FDA's Pe­ter Marks says

Last year
FDA+

In­ter­nal doc­u­ments shed new light on Sarep­ta FDA de­ci­sion, which top agency of­fi­cial says was ‘ex­cep­tion­al’

Last year
FDA+

BeiGene ends pact with Shore­line, its 'en­try in­to cell ther­a­py'

Last year
Startups
Deals

Bio­Mar­in's Roc­ta­vian, once fore­cast to sell $50M to $150M last year, on­ly pulls in a frac­tion of that

Last year
Pharma

Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Last year
R&D

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Last year
R&D

FDA ap­proves Io­vance's cell ther­a­py for melanoma, the first treat­ment based on tu­mor-in­fil­trat­ing lym­pho­cytes

Last year
Pharma
FDA+

FDA sets June de­ci­sion dead­line for po­ten­tial full ap­proval, la­bel ex­pan­sion of Sarep­ta’s Duchenne gene ther­a­py

Last year
FDA+

Af­ter pa­tient out­cry, Taysha starts to of­fload drug pro­grams

Last year
R&D

Astel­las pur­sues ‘con­vert­ible’ in vi­vo CAR-T cell ther­a­pies with Kelo­nia Ther­a­peu­tics

Last year
Deals

Two SPAC’d biotechs raise ad­di­tion­al mon­ey as Bi­hua Chen’s blank check clos­es $184M IPO

Last year
Financing

CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

Last year
R&D
Pharma

Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

Last year
Financing
Startups

Kyver­na surges af­ter IPO, and CEO lays out plans for cell ther­a­py in im­mune dis­eases

Last year

Neu­rona rais­es $120M to take epilep­sy cell ther­a­py to late-stage de­vel­op­ment

Last year
Financing
Startups

BioN­Tech, Au­to­lus strike wide-rang­ing li­cens­ing and man­u­fac­tur­ing deal for CAR-T ther­a­pies

Last year
Deals
Manufacturing

Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Last year
Financing
Startups

Re­genxbio to seek ac­cel­er­at­ed ap­proval of Hunter syn­drome gene ther­a­py us­ing bio­mark­er da­ta

Last year
R&D
First page Previous page 891011121314 Next page Last page
A service from the Financial Times